Posted On: 09/14/2014 10:43:57 AM
Post# of 30065
24 Updates to AMBS Pipeline
01.) LymPro - 72 Patient LP-002 Clinical Study Enrollment (completed)
02.) LymPro - LP-002 clinical performance data results (est. Sept.)
03.) Lympro - JV Partnership Agreement (est. 4Q14)
04.) LymPro - TBI / CTE update studies
05.) LymPro - CLIA submission / CLIA launch (est. 4Q14)
06.) Eltoprazine - signif. announcements, incl. 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
08.) MANF RP - functional genetic mouse data & addit. efficacy data sets (est. 4Q14)
09.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
10.) MANF RP - Orphan Drug Designation (ODD) potential - (est. 4Q14)
11.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
12.) MANF DB-1 Wolframs - orphan potential - (est. 4Q14)
13.) MANF - addit. data from undisclosed activities
14.) MANF - Good Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)
15.) PhenoGuard - JV Partnership update potential
16.) PhenoGuard - discovery of 2nd protein family
17.) PhenoGuard - transformed into 1st rationally designed NF discovery platform
18.) PhenoGuard - evaluation of external drug candidates for in-licensure potential
19.) NuroPro - preparing Ph. 2 CLIA validation study
20.) potential - financial engineering (est. 9/22 ASM)
21.) potential - multiple grant funding
22.) potential - new acquisition / Cerora AD scanner
23.) potential - diagnostics div. spin off
24.) NASDAQ uplisting - (est. 4Q14)
***** Note: all above items were abstracted from both the AMBS Chairmans Blog, dated 8/10/14, and Crystal Research Co. Report, dated 9/8/14
01.) LymPro - 72 Patient LP-002 Clinical Study Enrollment (completed)
02.) LymPro - LP-002 clinical performance data results (est. Sept.)
03.) Lympro - JV Partnership Agreement (est. 4Q14)
04.) LymPro - TBI / CTE update studies
05.) LymPro - CLIA submission / CLIA launch (est. 4Q14)
06.) Eltoprazine - signif. announcements, incl. 200 patient Ph. 2b trial PD-LID (est. 4Q14)
07.) MANF - Ophthalmological ear toxicology complete data sets (est. 4Q14)
08.) MANF RP - functional genetic mouse data & addit. efficacy data sets (est. 4Q14)
09.) MANF / GDNF - Renishaw CED Ph. 2B test trial results (est. 4Q14)
10.) MANF RP - Orphan Drug Designation (ODD) potential - (est. 4Q14)
11.) MANF DB-1 Wolframs - Retinal eye data test results (est. 4Q14)
12.) MANF DB-1 Wolframs - orphan potential - (est. 4Q14)
13.) MANF - addit. data from undisclosed activities
14.) MANF - Good Mfg. Practices (GMP) for 1st in-man studies (est. 4Q14)
15.) PhenoGuard - JV Partnership update potential
16.) PhenoGuard - discovery of 2nd protein family
17.) PhenoGuard - transformed into 1st rationally designed NF discovery platform
18.) PhenoGuard - evaluation of external drug candidates for in-licensure potential
19.) NuroPro - preparing Ph. 2 CLIA validation study
20.) potential - financial engineering (est. 9/22 ASM)
21.) potential - multiple grant funding
22.) potential - new acquisition / Cerora AD scanner
23.) potential - diagnostics div. spin off
24.) NASDAQ uplisting - (est. 4Q14)
***** Note: all above items were abstracted from both the AMBS Chairmans Blog, dated 8/10/14, and Crystal Research Co. Report, dated 9/8/14
(0)
(0)
